Book Book

Dark Remedy: The Impact of Thalidomide and its Revival as a Vital Medicine

BMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7302.1608 (Published 30 June 2001) Cite this as: BMJ 2001;322:1608
  1. Martin Schulz, head, centre for drug information and pharmacy practice
  1. ABDA-Federal Union of German Associations of Pharmacists, Eschborn, Germany

    Trent Stephens, Rock Brynner


    Embedded Image

    Perseus Publishing, £18.99, pp 228 ISBN 0 7382 0404 8

    Rating: Embedded ImageEmbedded ImageEmbedded Image

    In 1982, when I was a graduate student at the Institute of Pharmacology at the University of Hamburg, I became personally involved with thalidomide (by that time better known in Germany as Contergan) for the first time. Of course, during university training every medical and pharmacy student learned that the so called Contergan disaster was the driving force behind a drug approval process that was concerned with both efficacy and, most importantly, safety. However, what lasts forever is the …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe